Materialise N.V. (MTLS)

BE — Technology Sector

Peers: IMMR ONTF LAW PRLB VCYT SSYS TWST

Automate Your Wheel Strategy on MTLS

With Tiblio's Option Bot, you can configure your own wheel strategy including MTLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol MTLS
Rev/Share 4.4956
Book/Share 4.2225
PB 1.0213
Debt/Equity 0.2151
CurrentRatio 2.1601
ROIC 0.0241

MktCap 254798722.854
FreeCF/Share 0.0261
PFCF 165.5612
PE 45.2813
Debt/Assets 0.1327
DivYield 0
ROE 0.0226

Rating B
Score 3
Recommendation Neutral
P/E Score 1
DCF Score 4
P/B Score 4
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Materialise NV (MTLS) Q2 2025 Earnings Call Transcript

MTLS
Published: July 24, 2025 by: Seeking Alpha
Sentiment: Neutral

Materialise NV (NASDAQ:MTLS ) Q2 2025 Earnings Conference Call July 24, 2025 8:30 AM ET Company Participants Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux, Research Division Troy Donavon Jensen - Cantor Fitzgerald & Co., Research Division Harriet Fried - Unidentified Company Operator Good day, and thank you for standing by. Welcome to the Second Quarter 2025 Materialise NV Financial Results Conference Call.

image for news Materialise NV (MTLS) Q2 2025 Earnings Call Transcript

Materialise Q2 Preview: Anticipating Strong Medical Growth; Initiating With 'Buy'

MTLS
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive

I rate Materialise a 'buy' with a fair value of $8.83, driven by its unique integrated 3D printing software and hardware solutions. Materialise's strategic focus on software and medical segments strengthens its competitive edge, with medical now 47% of revenue and growing double digits. Recurring software revenue exceeds 80% in its segment, supporting margin expansion, customer retention, and reducing business cyclicality.

image for news Materialise Q2 Preview: Anticipating Strong Medical Growth; Initiating With 'Buy'

Materialise NV to Report Second Quarter 2025 Earnings on Thursday, July 24, 2025

MTLS
Published: July 10, 2025 by: Business Wire
Sentiment: Neutral

LEUVEN, Belgium--(BUSINESS WIRE)--Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and of sophisticated 3D printing services, today announced that it will release financial results for the second quarter ended June 30, 2025 on Thursday, July 24, 2025 at 6:30 a.m. ET/12:30 p.m. CET. Senior management will hold a conference call to discuss the second quarter 2025 financial results on Thursday, July 24, 2025 at 8:30 a.m. ET/2:30 p.m. CET. To access the call by p.

image for news Materialise NV to Report Second Quarter 2025 Earnings on Thursday, July 24, 2025

Materialise to Hold Annual Shareholders' Meeting and Extraordinary Shareholders' Meeting on June 3, 2025

MTLS
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

LEUVEN, Belgium, May 16, 2025 (GLOBE NEWSWIRE) -- Materialise NV (NASDAQ:MTLS), a leading provider of additive manufacturing software and sophisticated 3D printing solutions, today announced that it will host its Annual General Shareholders' Meeting (AGM) on Tuesday, June 3, 2025, at 10:00 am CET.

image for news Materialise to Hold Annual Shareholders' Meeting and Extraordinary Shareholders' Meeting on June 3, 2025

Materialise: Medical Segment Continues To Thrive

MTLS
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Positive

While Materialise's Q1 results were mixed they exceeded low investor expectations, with the company's Medical segment continuing to excel. Market conditions are likely to remain challenging, but lower energy costs and increased defense spending in Europe could help to offset this. Materialise's Medical segment alone more than justifies its current market capitalization.

image for news Materialise: Medical Segment Continues To Thrive

Materialise: Manufacturing Headwinds Are A Distraction

MTLS
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Negative

Materialise: Manufacturing Headwinds Are A Distraction

Materialise NV (MTLS) Q4 2024 Earnings Call Transcript

MTLS
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral

Materialise NV (NASDAQ:MTLS ) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Company Participants Harriet Fried - Investor Relations Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux Troy Jensen - Cantor Fitzgerald Operator Ladies and gentlemen thank you for standing by. Welcome to the Fourth Quarter 2024 Materialise Financial Results Conference Call.

image for news Materialise NV (MTLS) Q4 2024 Earnings Call Transcript

About Materialise N.V. (MTLS)

IPO Date 2014-06-25
Website https://www.materialise.com
Industry Software - Application
CEO Brigitte de Vet-Veithen
Employees 488

Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. Its Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The company's Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. Its Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.